Jan 27 2010
Tranzyme Pharma today announced that the United States Adopted Name
Council (USAN) has approved the generic name “ulimorelin” for Tranzyme’s
novel, late-stage, prokinetic agent TZP-101. Ulimorelin, if approved, is
expected to be a first-in-class drug for the treatment of
gastrointestinal (GI) dysmotility indications in acute care
(hospital-based) settings. Ulimorelin is a small molecule,
intravenously-administered drug that targets the ghrelin receptor;
ghrelin is responsible for energy homeostasis, appetite regulation and
gastro-intestinal motility. The safety and pharmacokinetic profiles of
ulimorelin have been extensively characterized in healthy subjects and
patients across multiple dose levels, and the GI prokinetic properties
of the compound have been well established in humans.
“Macrocycle-Based
Drug Discovery: The Ulimorelin Story, at the upcoming Cambridge
Healthtech Institute’s 17th International Molecular Medicine
Tri-Conference being held February 3-5, 2010 in San Francisco, CA.”
To date, ulimorelin has been successfully studied in two international
Phase 2 trials, one for the management of postoperative ileus (POI) and
a second for the treatment of acute gastroparesis, and has the potential
to treat other conditions where a safe and effective GI prokinetic
therapy is desired in acute care settings.
Helmut Thomas, PhD, DABT, Tranzyme’s Senior Vice President of Research
and Preclinical Development, will present the case study, “Macrocycle-Based
Drug Discovery: The Ulimorelin Story, at the upcoming Cambridge
Healthtech Institute’s 17th International Molecular Medicine
Tri-Conference being held February 3-5, 2010 in San Francisco, CA.
Research shows "Alzheimer's in a dish" model can accelerate drug discovery